Trevi Therapeutics Inc (OQ:TRVI)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 195 Church St Fl 14
NEW HAVEN CT 06510-2009
Tel: 1-203-9039627
Website: https://www.trevitherapeutics.com
IR: See website
<
Key People
Jennifer L. Good
President, Chief Executive Officer, Director
Thomas R. Sciascia
Co-Founder, Chief Science Officer
Lisa Delfini
Chief Financial Officer
David Clark
Chief Medical Officer
Farrell Simon
Chief Commercial Officer
 
Business Overview
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed k-opioid receptor agonist and mu-opioid receptor antagonist. It is conducting Phase IIb/III clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. It has also conducted a Phase II clinical trial of Haduvio for chronic cough in patients with IPF, which is referred to as the Phase II CANAL trial. The Company's Haduvio development programs include Chronic Cough in IPF Program, RCC Program and Prurigo Nodularis Program. The Company's subsidiary is Trevi Therapeutics Limited.
Financial Overview
For the fiscal year ended 31 December 2023, Trevi Therapeutics Inc revenues was not reported. Net loss increased less than 1% to $29.1M., offset by Pharmaceuticals segment loss increase of 13% to $33.9M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.45 to -$0.29.
Employees: 25 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $125.44M as of Dec 31, 2023
Annual revenue (TTM): $0.00M as of Dec 31, 2023
EBITDA (TTM): -$33.80M as of Dec 31, 2023
Net annual income (TTM): -$29.07M as of Dec 31, 2023
Free cash flow (TTM): -$31.85M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 68,960,167 as of Mar 20, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.